Navigation Links
Clinical Genomics Pty Ltd and The Garvan Institute of Medical Research Enter into Licensing Agreement

SYDNEY, Sept. 27 /PRNewswire/ -- Clinical Genomics Pty. Ltd (Sydney, Australia) and The Garvan Institute of Medical Research (Sydney, Australia) today announced that they have entered into a license agreement in relation to novel biomarkers discovered by scientists at the Garvan Institute. Under the terms of the agreement, Clinical Genomics obtains worldwide exclusive rights to the Garvan's proprietary cancer associated methylation DNA biomarkers for the diagnosis and or treatment of colorectal cancer. Clinical Genomics intends to expand its colorectal biomarker research program to evaluate these promising biomarkers in view of formulating a diagnostic test utilizing those biomarkers demonstrating clinical benefit for the early detection of colorectal cancer.

"Through this strategic licensing agreement with the Garvan Institute, we have complemented our existing technology portfolio and enhanced our ability to develop next generation products for diagnosing colorectal cancer at the earliest, most treatable stage," stated Dr. Lawrence LaPointe, Chief Executive Officer of Clinical Genomics. "We have also broadened our product development options for ourselves and our partners."

"This licensing agreement will allow Clinical Genomics to achieve the full diagnostic potential of the colorectal cancer biomarkers identified by our researchers," said Professor John Shine, Executive Director of Garvan. "Our hope is that the company will successfully develop a diagnostic tool that will be useful in the global effort to treat this common cancer."

About DNA Methylation

DNA methylation is a naturally occurring biological process involved in gene silencing. In 2005, a team led by Prof. Susan Clarke at the Garvan Institute of Medical Research published a paper in Nature Genetics describing a region of the human genome that shows much higher levels of methylation (silencing) in colorectal cancer compared to healthy controls.

About The Garvan Institute of Medical Research

The Garvan Institute of Medical Research is a world class institute focused on gene-based medical research with a strong focus on cancer and metabolic syndromes. World leading DNA methylation researcher Professor Susan Clark is the director of epigenetics research at the Garvan. Prof. Clark's track record includes pioneering the development of the bisulphite sequence protocol for detecting methylated cytosines now used around the world to measure gene silencing, discovery of the hyper-methylation of GSTP1 in prostate cancer and, more recently, contributions to understanding genome-wide methylation patterns in cancer.

About Clinical Genomics Pty Ltd

Clinical Genomics was formed in September 2006 to develop, extend, and commercialise molecular markers for colorectal disease. The enterprise includes experts in the science and business of colorectal cancer detection as well as institutional, commercial and clinical collaborative partners that understand this field. On top of a solid foundation of intellectual property protecting a panel of neoplasia biomarkers, CG has attracted significant financial and human resources to address this opportunity. By applying advanced biotechnology and computational technologies to study the complex changes in gene expression that occur as normal colorectal cells become cancerous, Clinical Genomics expect that an understanding of the molecular basis of the disease will enable them to provide products for improved diagnosis, management and possibly therapy of this disease.   Further Information:   Dr. Lindsay Collinson   Ph: +61 2 9888 9065 x 206   E:   Clinical Genomics Pty Ltd

SOURCE Clinical Genomics Pty Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InspireMD Presents 2 Years Clinical Outcome of MGuard Multicenter Experience in STEMI Patients. The New Superb Clinical Results Were celebrated at InspireMDs TCT Satellite Symposium in Washington DC., Today.
2. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
3. China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic
4. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
5. Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus
6. 2010 Lasker Awards Honor Trailblazers in Medical Research and Clinical Care
7. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
8. Stemedica Announces Completion of Clinical Stem Cell Master Bank
9. Paratek to Present Clinical Data at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. ChromaDex Commences a Clinical Trial on pTeroPure™ Pterostilbene
11. InSightec Treats First Prostate Cancer Patients in Clinical Trials
Post Your Comments:
(Date:10/9/2015)... On October 8, the Honorable Doris O. ... recognizing the third annual International Plasma Awareness Week (IPAW), ... the Plasma Protein Therapeutics Association (PPTA) and ... , Raise global awareness about plasma donation , ... improving lives , Increase understanding about lifesaving plasma ...
(Date:10/9/2015)... ROCKVILLE, Md. , Oct. 9, 2015 /PRNewswire/ ... developing next generation vaccines based on the LAMP-vax ... an exclusive worldwide licensing agreement with Astellas Pharma ... prevention of any and all allergic diseases in ... will receive an upfront payment of $300 million ...
(Date:10/9/2015)...  Pulmatrix, Inc., (NASDAQ: PULM ) will be webcasting ... th Annual BIO Investor Forum on Tuesday, ... --> th Annual BIO Investor Forum ... pm EDT). --> Pulmatrix will be presenting ... on Thursday, October 15, 2015 at 8:30 am EDT. Additionally, ...
(Date:10/9/2015)... ... October 09, 2015 , ... Leading microbial genomics startup uBiome today launched the ... relationship between weight management and the microbiome. The study uses the ResearchKit framework, designed ... iPhone app. , The uBiome app is available as a free download from the ...
Breaking Biology Technology:
(Date:9/24/2015)... , September 24, 2015 ... 25 september 2015 Kerv ( ... digitala finanstjänster, lanserar idag världens första kontaktlösa ... samla in 77 000 GBP för massproduktion ... ) , Kerv-bärare ...
(Date:9/10/2015)... -- Report Details The global wearable technology ... expectations of revenues, consumer adoption and even technological advances. ... wearables begin to achieve that mass market acceptance that ... is the entrance of Apple to the SmartWatches market, ... the overall size of the wearable technology market. ...
(Date:9/9/2015)... , Sept. 9, 2015  NuData Security announced ... solution-based milestones, furthering the company,s commitment to protecting ... fraud. NuData Security,s online fraud detection ... company,s growth cycle. The product combines continual analysis ... good user behavior from fraudulent behavior, allowing the ...
Breaking Biology News(10 mins):